Gabather

0.03 SEK

-7.30 %

Less than 1K followers

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-7.30 %

-6.78 %

-13.16 %

-32.10 %

-69.03 %

-69.79 %

-97.30 %

-97.70 %

-99.22 %

Gabather is a pharmaceutical company whose business focus is to develop drug candidates for the treatment of neurological diseases. The focus is particularly on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Market cap

13.51M SEK

Turnover

44.1K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

15.12

2025

Extraordinary general meeting '25

26.2

2026

Annual report '25

29.5

2026

Interim report Q1'26

All

Press releases

3rd party

ShowingAll content types

Third party research12/1/2025, 1:57 PM

Gabather: Eager to start the TOTEMS study - VH Corp

* A TOTEMS study article published in Frontiers in Psychiatry * The exercise of TO 7 warrants provides some financial relief * We keep our fair value of SEK 0.092 per share Gabather's reported figures in its recent Q3 report were close to our estimates...

Press release12/1/2025, 1:45 PM

Västra Hamnen Market Focus: Gabather: Eager to start the TOTEMS study

Third party research9/1/2025, 10:05 AM

Gabather: TOTEMS-study delayed, not derailed - VH Corp

* Issues with clinical test material delays TOTEMS-study * New chairman elected at the AGM * We keep our fair value of SEK 0.092 per share Before releasing its Q2 2025 report, Gabather announced that the TOTEMS-study would be delayed due to issues with...

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release9/1/2025, 10:00 AM

Västra Hamnen Market Focus: Gabather: TOTEMS-study delayed, not derailed

Third party research6/19/2025, 8:27 AM

Gabather: High potential in specific modulation - VH Corp

• Novel therapeutics addressing the GABAA receptor system in the CNS • An exploratory phase II study in schizophrenia is ongoing • We initiate coverage with a fair value of SEK 0.092 per share Gabather is a drug developer in precision medicine targeting...

Third party research3/6/2025, 8:55 AM

Gabather: Redefining Cognitive Disorder Treatment - Analyst Group

Gabather AB (“Gabather” or “the Company”) is advancing GT-002, a first-in-class GABAA-modulator, through Phase II clinical trials, targeting cognitive dysfunction. With a fully funded schizophrenia Phase II trial and a planned expansion into Phase II...

Regulatory press release1/13/2025, 7:30 AM

Gabather AB appoints Pareto Securities AB to act as a liquidity provider for the Company's share

Regulatory press release4/10/2024, 11:00 AM

Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

Press release3/18/2024, 7:30 AM

Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Press release3/7/2024, 8:02 AM

Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study

Regulatory press release12/22/2023, 2:03 PM

Gabather AB receives initial EEG data analysis from the GT-002 target engagement study

Regulatory press release12/14/2023, 8:16 AM

Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)

Regulatory press release12/11/2023, 12:23 PM

Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG

Regulatory press release10/12/2023, 12:00 PM

Gabather AB: Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers

Regulatory press release4/13/2023, 6:45 AM

Gabather AB: Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957

Regulatory press release6/7/2022, 8:57 AM

Gabather AB, receives Notice of Allowance from the U.S. Patent Office for its U.S. patent application publication No. US 2021/0087193 A1

Press release6/2/2022, 8:00 AM

Gabather AB: BioStock: Gabather's lead candidate moves forward in the clinic

Regulatory press release5/17/2022, 1:36 PM

Gabather AB: Gabather receives approval to start the EEG/fMRI target engagement study with the drug candidate GT-002

Regulatory press release3/22/2022, 8:00 AM

Gabather AB invited by the Alzheimer's Drug Discovery Foundation, USA to submit a grant application to expand the studies with GT-002 in preclinical models of Alzheimer's disease

Regulatory press release9/14/2021, 6:37 AM

Gabather AB: BioStock: Gabather poised to complete phase I with GT-002

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.